StreetInsider.com News Articles

Form 4 Pulmonx Corp For: Jun 01 Filed by: Radhakrishnan Srikanth

Wed, 03 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260603/26599131.html

Form 4 Pulmonx Corp For: Jun 01 Filed by: Radhakrishnan Srikanth

Wed, 03 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260603/26599131.html

Form 4 Pulmonx Corp For: Jun 01 Filed by: Lehman David Aaron

Wed, 03 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260603/26599113.html

Form 4 Pulmonx Corp For: Jun 01 Filed by: Lehman David Aaron

Wed, 03 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260603/26599113.html

Form 4 Pulmonx Corp For: Jun 01 Filed by: French Glendon E. III

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599049.html

Form 4 Pulmonx Corp For: Jun 01 Filed by: French Glendon E. III

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599049.html

Form 4 Pulmonx Corp For: Jun 01 Filed by: Rose Geoffrey Beran

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599085.html

Form 4 Pulmonx Corp For: Jun 01 Filed by: Rose Geoffrey Beran

Wed, 03 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26599085.html

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company’s Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

Form SD Pulmonx Corp

Tue, 19 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26516548.html

Form SD Pulmonx Corp

Tue, 19 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26516548.html

Form 10-Q Pulmonx Corp For: Mar 31

Mon, 04 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260504/26426466.html

Form 10-Q Pulmonx Corp For: Mar 31

Mon, 04 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260504/26426466.html

Pulmonx Corporation (LUNG) Tops Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance

Wed, 29 Apr 2026 16:25:29 -0400

Pulmonx Corporation (NASDAQ: LUNG) reported Q1 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $22.65 million.

GUIDANCE:

Pulmonx Corporation sees FY2026 revenue of $90-92 million, versus the consensus of $90.9 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

Pulmonx Corporation (LUNG) Tops Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance

Wed, 29 Apr 2026 16:25:29 -0400

GUIDANCE:

Pulmonx Corporation sees FY2026 revenue of $90-92 million, versus the consensus of $90.9 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

Form 8-K Pulmonx Corp For: Apr 29

Wed, 29 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260429/26394961.html

Form 8-K Pulmonx Corp For: Apr 29

Wed, 29 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260429/26394961.html

Pulmonx Reports First Quarter 2026 Financial Results

Wed, 29 Apr 2026 16:05:00 -0400

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026.

Recent Highlights

Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis
Delivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decrease
Delivered $7.3

Pulmonx Reports First Quarter 2026 Financial Results

Wed, 29 Apr 2026 16:05:00 -0400

Recent Highlights

Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis
Delivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decrease
Delivered $7.3

Pulmonx Reports First Quarter 2026 Financial Results

Wed, 29 Apr 2026 16:05:00 -0400

Recent Highlights

Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis
Delivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decrease
Delivered $7.3

Pulmonx Reports First Quarter 2026 Financial Results

Wed, 29 Apr 2026 16:05:00 -0400

Recent Highlights

Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis
Delivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decrease
Delivered $7.3

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

Tue, 28 Apr 2026 16:05:00 -0400

REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in